Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425358 | 0.75 | GPR3 (0.41) | TSHRTRPA1POLBMEN1KMT2A | |
| SCHEMBL3157929 | 0.73 | MEN1 (0.52) | TSHRPOLBMEN1KMT2AATM | |
| SCHEMBL28956524 | 0.70 | HTR2A (0.39) | TSHRPOLBMEN1KMT2AATM | |
| SCHEMBL10455242 | 0.69 | MEN1 (0.53) | TSHRPOLBMEN1KMT2AATM | |
| Hydrochloric Acid SCHEMBL8677554 | 0.69 | MEN1 (0.44) | TSHRPOLBMEN1KMT2AATM | |
| Hydrochloric Acid SCHEMBL8676449 | 0.69 | MEN1 (0.44) | TSHRPOLBMEN1KMT2AATM | |
| SCHEMBL12259452 | 0.69 | CYP1A2 (0.46) | TSHRPOLBMEN1KMT2AATM | |
| SCHEMBL7355279 | 0.69 | CHRNB4 (0.53) | CHRNB4CHRNA3TSHRTRPA1 | |
| SCHEMBL27887187 | 0.69 | MEN1 (0.44) | TSHRPOLBMEN1KMT2AATM | |
| Hydrochloric Acid SCHEMBL8676454 | 0.69 | MEN1 (0.44) | TSHRPOLBMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141674-B2 | Anti-inflammatory compounds | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040082601-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2004-04-29 | — | — | US | disclosed |
| CN-1123564-C | Anti-inflammatory compounds | ORTHO MCNEIL PHARMACEUTICAL CO (US) | 2003-10-08 | — | — | CN | disclosed |
| US-20030171585-A1 | Triphenylpropanamide compounds | SCOTT MALCOLM K (US) | 2003-09-11 | — | — | US | disclosed |
| US-6509369-B2 | Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020103217-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2002-08-01 | — | — | US | disclosed |
| EP-0966430-B1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO MCNEIL PHARM INC (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | disclosed |
| CN-1249742-A | Anti-inflammatory compounds | ORTHO MCNEIL PHARMACEUTICAL CO (US) | 2000-04-05 | — | — | CN | disclosed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082601-A1 | Anti-inflammatory compounds | TNF, PTGES, PTGES2 | CHRNB4 4634/4885CHRNA3 4557/4885TSHR 4802/4885 |
| US-20030171585-A1 | Triphenylpropanamide compounds | PTGES, PTGES2, MPO | CHRNB4 3201/4885CHRNA3 2936/4885TSHR 3768/4885 |
| US-20020103217-A1 | Anti-inflammatory compounds | TNF, PTGES, PTGES2 | CHRNB4 4634/4885CHRNA3 4557/4885TSHR 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.